Literature DB >> 24157551

ETV1 positively regulates transcription of tumor suppressor ARF.

Evan Zynda1, Mark W Jackson2, Partho Bhattacharya1, Eugene S Kandel1.   

Abstract

ETV1 (ETS variant 1) is a transcription factor from the ETS family and an oncogene in several types of human malignancies. Paradoxically, a predicted inactivating mutation in ETV1 was previously found in a clone of HT1080 cells with reduced activity of p53. We report that elevated expression of ETV1 makes p53-null tumor cells hypersensitive to restoration of said tumor suppressor. Furthermore, elevated levels of either wild-type ETV1 or its truncated derivative, dETV1, which mimics the product of an oncogenic rearrangement in certain tumors, results in increased expression of mRNA for p14ARF, a known activator of p53. Accordingly, expression of a luciferase reporter, which is driven by a putative ARF promoter, was elevated by concomitant expression of either ETV1 or dETV1. Our observations point to yet another example of a tumor suppressor gene being activated by a potentially oncogenic signal. A better understanding of the mechanisms that allow a cell to bypass such safeguards is needed in order to predict and prevent the development of an oncogene-tolerant state during cancer evolution.

Entities:  

Keywords:  ETV1; oncogenic transformation; p14ARF; p53; tumor suppression

Mesh:

Substances:

Year:  2013        PMID: 24157551      PMCID: PMC3912040          DOI: 10.4161/cbt.26883

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  58 in total

1.  An oncogenic role for ETV1 in melanoma.

Authors:  Judit Jané-Valbuena; Hans R Widlund; Sven Perner; Laura A Johnson; Aurora C Dibner; William M Lin; Alissa C Baker; Rosalynn M Nazarian; Krishna G Vijayendran; William R Sellers; William C Hahn; Lyn M Duncan; Mark A Rubin; David E Fisher; Levi A Garraway
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

2.  ETS rearrangements and prostate cancer initiation.

Authors:  Brett S Carver; Jennifer Tran; Zhenbang Chen; Arkaitz Carracedo-Perez; Andrea Alimonti; Caterina Nardella; Anuradha Gopalan; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

3.  Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo.

Authors:  Gong-Hong Wei; Gwenael Badis; Michael F Berger; Teemu Kivioja; Kimmo Palin; Martin Enge; Martin Bonke; Arttu Jolma; Markku Varjosalo; Andrew R Gehrke; Jian Yan; Shaheynoor Talukder; Mikko Turunen; Mikko Taipale; Hendrik G Stunnenberg; Esko Ukkonen; Timothy R Hughes; Martha L Bulyk; Jussi Taipale
Journal:  EMBO J       Date:  2010-06-01       Impact factor: 11.598

4.  Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

Authors:  Sook Shin; Tae-Dong Kim; Fang Jin; Jan M van Deursen; Scott M Dehm; Donald J Tindall; Joseph P Grande; Jan-Marie Munz; George Vasmatzis; Ralf Janknecht
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

5.  Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.

Authors:  Karin G Hermans; Hetty A van der Korput; Ronald van Marion; Dennis J van de Wijngaart; Angelique Ziel-van der Made; Natasja F Dits; Joost L Boormans; Theo H van der Kwast; Herman van Dekken; Chris H Bangma; Hanneke Korsten; Robert Kraaij; Guido Jenster; Jan Trapman
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 6.  ETS gene fusions in prostate cancer.

Authors:  Jeremy P Clark; Colin S Cooper
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

Review 7.  TP53 status and response to chemotherapy in breast cancer.

Authors:  Philippe Bertheau; Marc Espié; Elisabeth Turpin; Jacqueline Lehmann; Louis-François Plassa; Mariana Varna; Anne Janin; Hugues de Thé
Journal:  Pathobiology       Date:  2008-06-10       Impact factor: 4.342

8.  p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.

Authors:  Charlene E Kan; John T Patton; George R Stark; Mark W Jackson
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

9.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Authors:  Ping Chi; Yu Chen; Lei Zhang; Xingyi Guo; John Wongvipat; Tambudzai Shamu; Jonathan A Fletcher; Scott Dewell; Robert G Maki; Deyou Zheng; Cristina R Antonescu; C David Allis; Charles L Sawyers
Journal:  Nature       Date:  2010-10-03       Impact factor: 49.962

10.  A functional screen for regulators of CKDN2A reveals MEOX2 as a transcriptional activator of INK4a.

Authors:  Jeffrey T Irelan; Ana Gutierrez Del Arroyo; Abel Gutierrez; Gordon Peters; Kim C Quon; Loren Miraglia; Sumit K Chanda
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more
  3 in total

1.  Molecular Mechanism of β-Catenin Signaling Pathway Inactivation in ETV1-Positive Prostate Cancers.

Authors:  Sharif Morsalin; Chunshu Yang; Jinbo Fang; Sampreet Reddy; Shubhalaxmi Kayarthodi; Ed Childs; Roland Matthews; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2015-09

2.  MicroRNA analysis suggests an additional level of feedback regulation in the NF-κB signaling cascade.

Authors:  Peter Mechtler; Ruchi Singhal; Julia V Kichina; Jonathan E Bard; Michael J Buck; Eugene S Kandel
Journal:  Oncotarget       Date:  2015-07-10

3.  miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1.

Authors:  Ronit Cohen; Eyal Greenberg; Yael Nemlich; Jacob Schachter; Gal Markel
Journal:  Oncotarget       Date:  2015-08-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.